Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma
M. A. Smith(National Cancer Institute), Réka Simon, Richard S. Ungerleider(Theradex Oncology (United States)), Marc E. Horowitz(National Cancer Institute)
Cited by 204
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
|Biochemistry|1981|375
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas.
|Journal of Clinical Oncology|1996|353
Representation of older patients in cancer treatment trials
|Cancer|1994|349